De novo lupus nephritis during treatment with belimumab

OBJECTIVE: In light of reports of de novo LN during belimumab (BLM) treatment, we sought to determine its frequency and contributing or protective factors in a real-life setting. METHODS: Patients with SLE who received BLM between 2011 and 2017 at five European academic practices were enrolled (n = ...

Descripción completa

Detalles Bibliográficos
Autores principales: Parodis, Ioannis, Vital, Edward M, Hassan, Sabih-Ul, Jönsen, Andreas, Bengtsson, Anders A, Eriksson, Per, Leonard, Dag, Gunnarsson, Iva, Rönnblom, Lars, Sjöwall, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409994/
https://www.ncbi.nlm.nih.gov/pubmed/33341888
http://dx.doi.org/10.1093/rheumatology/keaa796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409994/
https://www.ncbi.nlm.nih.gov/pubmed/33341888
http://dx.doi.org/10.1093/rheumatology/keaa796

Ejemplares similares